InicioBSLN • SWX
add
Basilea Pharmaceutica AG Allschwil
Cierre anterior
41,15 CHF
Intervalo diario
40,60 CHF - 41,45 CHF
Intervalo anual
32,00 CHF - 49,00 CHF
Cap. bursátil
540,62 M CHF
Volumen medio
17,18 mil
Relación precio-beneficio
47,10
Rentabilidad por dividendo
-
Bolsa de valores principal
SWX
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
(CHF) | dic 2023info | Cambio interanual |
---|---|---|
Ingresos | 36,36 M | -19,30 % |
Gastos operativos | 7,96 M | 12,34 % |
Ingresos netos | -10,69 M | -187,82 % |
Margen de beneficio neto | -29,41 | -208,81 % |
Beneficios por acción | — | — |
EBITDA | -7,88 M | -152,08 % |
Tipo impositivo efectivo | 0,08 % | — |
Balance general
Activos totales
Responsabilidades totales
(CHF) | dic 2023info | Cambio interanual |
---|---|---|
Efectivo y a corto plazo | 59,93 M | -29,21 % |
Activos totales | 173,29 M | -21,53 % |
Responsabilidades totales | 183,29 M | -24,12 % |
Patrimonio total | -10,00 M | — |
Acciones en circulación | 12,00 M | — |
Precio-valor contable | -49,58 | — |
Rentabilidad económica | -11,81 % | — |
Retorno sobre capital | -17,26 % | — |
Flujo de caja
Variación neta del flujo de caja
(CHF) | dic 2023info | Cambio interanual |
---|---|---|
Ingresos netos | -10,69 M | -187,82 % |
Efectivo de operaciones | -3,81 M | -210,31 % |
Efectivo de inversión | -322,50 mil | -100,69 % |
Efectivo de financiación | -20,11 M | -4,52 % |
Variación neta del flujo de caja | -24,31 M | -178,80 % |
Flujo de caja libre | -4,62 M | -154,24 % |
Información sobre la empresa
Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and mucormycosis. Basilea is publicly traded on the SIX Swiss exchange.
The company is based in Basel, Switzerland. It has subsidiaries in France, Germany, Denmark, the People's Republic of China, Spain, the United Kingdom, and the United States of America. According to stock filings, it had 196 employees as of June 2007.
Among the company's notable products is Isavuconazole, an intravenous and oral antifungal, which received orphan drug status designation by the United States Food and Drug Administration in 2013. The company also manufactures pharmaceuticals for use against methicillin-resistant Staphylococcus aureus. Wikipedia
Director ejecutivo
Fundación
oct 2000
Sitio web
Empleados
147